CD274 and lung carcinoma: In 2016, pembrolizumab was shown to lead to a superior progression‐free survival (PFS) and overall survival (OS) compared to conventional chemotherapy in patients with lung cancer who had a high expression of programmed cell death‐ligand 1 (PD‐L1).4